Killian et al. investigated the effects of the chemokines CXCL-1 and CXCL-2 in prostate cancer cells and showed that CUR treatment significantly reduces CXCL-1 and CXCL-2 transcription [146]. This evidence concerns the gene CXCL2 and prostate carcinoma.